[HTML] springer.comFull View

[HTML][HTML] Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Y Li, T Mao, J Wang, H Zheng, Z Hu, P Cao… - Cell Communication and …, 2023 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …
被引用次数：17 相关文章

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.

Y Li, T Mao, J Wang, H Zheng, Z Hu… - Cell …, 2023 - search.ebscohost.com
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Y Li, T Mao, J Wang, H Zheng, Z Hu… - Cell …, 2023 - pubmed.ncbi.nlm.nih.gov
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …
[HTML] nih.gov

[HTML][HTML] Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Y Li, T Mao, J Wang, H Zheng, Z Hu, P Cao… - … and Signaling: CCS, 2023 - ncbi.nlm.nih.gov
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Y Li, T Mao, J Wang, H Zheng, Z Hu, P Cao… - … and Signaling: CCS, 2023 - europepmc.org
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …
[HTML] biomedcentral.com

[HTML][HTML] Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Y Li, T Mao, J Wang, H Zheng… - Cell …, 2023 - biosignaling.biomedcentral.com
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Y Li, T Mao, J Wang, H Zheng, Z Hu… - Cell …, 2023 - search.proquest.com
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.

Y Li, T Mao, J Wang, H Zheng, Z Hu, P Cao… - … and Signaling: CCS, 2023 - europepmc.org
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …
[PDF] biomedcentral.com

[PDF][PDF] Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

L Zhu, S Guo, X Zhao, Y Tian, H Shen, F Lin - 2023 - biosignaling.biomedcentral.com
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …